ArticleCancer medicine2023

The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.

Jie Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.